---
title: "Regen Biopharma files Form 15 for common"
url: "https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-26"
section: "Listings"
tickers: "OTC:RGBP"
source: "https://www.sec.gov/Archives/edgar/data/1589150/000149315224052071/form15-15d.htm"
summary: "The notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii)."
---

By the aibio.space news desk.

Sources

- [Regen Biopharma, Inc. 15-15D (2024-12-26)](https://www.sec.gov/Archives/edgar/data/1589150/000149315224052071/form15-15d.htm)

[RGBP](https://aibio.space/companies/regen-biopharma/)

2024-12-26

# Regen Biopharma files Form 15 for common and Series A preferred stock

Tickers [RGBP](https://aibio.space/companies/regen-biopharma/)

The notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).

## Key facts

- **Company**: Regen Biopharma, Inc. (OTC: RGBP)

- **News type**: Listings

- **Primary source**: [Regen Biopharma, Inc. 15-15D (2024-12-26)](https://www.sec.gov/Archives/edgar/data/1589150/000149315224052071/form15-15d.htm)

*The Capitol dome and spring blossom. Photo: Angie Drake, CC0, via Wordpress. The picture shows the field, not the companies named.*

Regen Biopharma, Inc. filed a Form 15 with the Securities and Exchange Commission covering its Common Stock and its Series A Preferred Stock. Form 15 is a certification and notice of termination of registration of a class of securities, or suspension of the duty to file reports under the Securities Exchange Act of 1934.

The company marked Rule 12h-3(b)(1)(ii) as the provision it relies on to terminate or suspend the duty to file reports. The filing lists no other class of securities for which a duty to file reports remains.

The notice gives the approximate number of holders of record as 482 for the common stock and 480 for the Series A Preferred Stock.

The company's principal executive offices are in La Mesa, California, and its Commission File Number is 333-191725. Once the duty to file reports ends, the company would no longer be required to file periodic reports such as annual and quarterly reports with the SEC.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

RGBP

Regen Biopharma, Inc.

OTC · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Regen Biopharma files Form 15 for common", 2024-12-26, https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/